Candel Therapeutics, Inc. Common Stock (CADL)
Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer. The company leverages its proprietary oncolytic viral platform to design and develop therapies aimed at stimulating the immune system to recognize and destroy tumors, with a focus on translating these therapies into effective solutions for patients with various types of cancer.
Company News
Candel Therapeutics published positive phase 1b clinical trial data on the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma patients, demonstrating a promising safety profile and potential survival benefit.
Candel Therapeutics' Interim Chief Financial Officer Charles Schoch sold over $63,000 worth of company stock to cover tax withholding obligations related to the vesting of restricted stock units. The transaction indicates continued investment in the company's future.
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents...